Examination of urinary decoy cells (DCs) is a useful screening test for the detection of polyomavirus (PV) replication. DC shed ding may precede or it is concurrently present with PV viremia and virusinduced interstitial nephritis. 1 The presence of DC, however, is not specific for the detection of renal parenchymal injury. DC is positive in up to 20% of stable renal allograft re cipients. Quantitative polymerase chain reaction (PCR) tests of urine and plasma are performed at some institutions as a single or an adjunctive procedure. 24 But these tests are expensive and their results usually come later than cytology. In addition to in creased risk for PV nephropathy, PV activation is associated with increased risk for acute rejection. 5 We have speculated that the amount of DCs can be a rough estimate of PV activation and used as a marker for immunomodulation. We therefore explored its significance in persistent shedding, PV nephropathy and acute rejection.
MATERIALS AND METHODS
During a period ranging from January 2003 to December 2011, a total of 1,956 urine samples were collected for DC test ing in 652 renal transplant recipients. Of these, 88 renal allograft patients who had DCs detected at least once in four or more urine samples (n=601), served as the DC shedding group. One hun dred fortytwo patients who had no DCs in four or more urine samples (n=734) served as the control group. The urinary DC test was routinely done on 1, 3, 6, 9, and 12 months after trans plant. If DCs were present, urine cytology was repeated at the next visit. After one year, the duration of urinary DC test be came irregular. In our series of patients, there was a variability in its duration. That is, the duration of urinary DC test was less than two consecutive years in 78.4% of total patients. In addi tion, it was more than two years in 21.6% of patients of the DC shedding group and 5.6% of patients of the control group.
The presence of DCs was originally reported as negative or no DCs, a few (13 DCs/10 high power field [ HPF ] in routine smear slides or in cytospin slide), several (49 DCs/10 HPF in routine smear slides or in cytospin slide) and many DCs (≥10 DCs/10 HPF in routine smear slides or in cytospin slide). 6 In the current study, we classified cases with a few and several DCs into the lowgrade (LG) shedding group and those with many DCs detected at least once during the study into the highgrade (HG) shedding group (Fig. 1) Background: Examination of urine for decoy cells (DCs) is a useful screening test for polyomavirus (PV) activation. We explored the significance of the amount of DCs in persistent shedding, PV nephropathy and acute rejection. Methods: A case-controlled study was performed in 88 renal allograft patients who had DCs detected at least once in four or more urine samples. Results: Fifty one patients were classified into the high-grade shedding group (HG) and 37 patients into the low-grade shedding group (LG) according to DC shedding ( ≥ 10 or < 10 DCs/10 high power field [HPF] ). DC shedding of more than three consecutive months was significantly more prevalent in the HG as compared with their LG counterparts (p< 0.0001). Urinary DCs were present for more than one year in 29.4% of the HG and 8.1% of the LG. Real-time polymerase chain reaction for PV was higher in both urine (51.4% vs. 11.1%) and plasma (9.1% vs. 0%) of the HG than the LG. The prevalence of PV nephropathy was higher in the HG than the LG (p= 0.019). However, there was no significant difference in the prevalence of acute rejection. Conclusions: Shedding of ≥ 10 DCs/10 HPF is associated with sustained shedding, polymerase chain reaction positivity and PV nephropathy, but not a predictor of acute rejection.
performed (Fig. 2 ). Urinary PV DNA replication was examined by quantitative realtime PCR in 35 patients of the HG shed ding group and nine patients of the LG shedding group. Plas ma PV DNA replication was examined by quantitative real time PCR in 33 patients of the HG shedding group and seven patients of the LG shedding group. The indications for renal al lograft biopsies were serum creatinine elevation, proteinuria of ≥1 g/24 hr or persistent microscopic hematuria. Thirtytwo renal allograft biopsies were performed from 88 DC positive patients, which were compared with 42 biopsies from 142 pa tients of the control group. The biopsy results were also com pared with the DC data. PV nephropathy was diagnosed by re nal biopsy when tubular epithelial cells with characteristic viral inclusion bodies showed SV40 immunoreactivity. Statistical analysis was done with the Chisquare method.
RESULTS
In the current study, 88 DCpositive patients who were as signed to the DC shedding group were classified into the HG shedding group (n=51) and the LG shedding group (n=37). Urinary DCs first appeared within three months in 29.5%, be tween three to six months in 23.9%, between six months to one year in 35.2% and more than one year posttransplant in 11.4% of our series of patients. DC shedding frequently waxed and waned. Sustained shedding was defined by the presence of DCs during a consecutive period of more than three months, and it occurred in 66.7% of patients of the HG shedding group and 18.9% of patients of the LG shedding group. Sustained shed ding was significantly more prevalent in patients of the HG group as compared with their LG counterparts (p<0.0001).
Fifteen patients (29.4%) of the HG shedding group had inter mittent secretion of DCs for more than one year and two patients did for more than three years. But only three patients (8.1%) of the LG shedding group had secretion of DCs for more than one year. At the latest followup, there was a persistent presence of DCs in 21 patients (41.2%) of the HG shedding group and four patients (10.8%) of the LG shedding group. The number of DCs was decreased in eight patients of the HG shedding group and two patients of the LG group and it was increased in two patients of the HG shedding group and one patient of the LG group (Table 1) .
Quantitative realtime PCR was positive with a range of 132,0006,150,000,000 copies/mL in urine samples collected from 18 of 35 patients of the HG shedding group and one of nine patients of the LG shedding group. Plasma PCR was posi tive with a range of 12,200593,000 copies/mL in three of 33 patients of the HG shedding group, but negative in patients of the LG shedding group. A diagnosis of PV nephropathy was made in seven patients of the HG group within a median peri od of 17 months (range, 4 to 28 months) posttransplant. Of the six patients with PV nephropathy, for whom the plasma and urine PCR were performed, five and two were positive for urinary and plasma PCR, respectively. The prevalence of PV nephropathy was higher in the HG shedding group than the LG shedding group (p=0.019). Immunosuppression was decreased in seven patients who were diagnosed with PV nephropathy. In nine patients of the HG shedding group who were not diagnosed with PV nephropathy, the dose of mycophenolate was lowered or its treatment was discontinued. DCs disappeared in three patients on 3, 4, and 7 months after modulation. The number of DCs was decreased in four patients, but they were persistently present in two patients. In six patients with viruria or viremia, confirmed on the real time PCR, however, the renal function was stable without im munomodulation.
Acute rejection episodes were proven on biopsy in seven pa tients of the HG shedding group and in 12 patients of the con trol group. Five patients of the HG shedding group shed DCs prior to the onset of acute rejection. Plasma PCR for PV was positive in one patient at the onset of acute rejection and it be came positive after treatment of acute rejection in one patient (Table 2 ). In addition, there was no significant difference in the prevalence of acute rejection between the HG shedding group and the control group (p=0.875).
DISCUSSION
The current study demonstrated that the degree of urinary DCs was correlated with sustained shedding, urinary PCR and development of PV nephropathy. The duration of urinary DC shedding was longer in the HG shedding group than LG shed ding group (shedding of more than one year, 29.4% vs. 8.1%; sustained shedding of more than three consecutive months, 66.7% vs. 18.9%). Urinary PCR was positive in 51.4% of pa tients of the HG shedding group and 11.1% of patients of the LG shedding group. In addition, plasma PCR was positive in 17.6% of patients of the HG shedding group who were posi tive for urine PCR. Furthermore, plasma PCR was negative in one patient of the LG shedding group who was positive for urine PCR. All the seven patients with PV nephropathy experienced HG shedding of DCs.
In our screening program of PV, the urinary DC test was per formed at a 1 and then 3month interval during the first post transplant year. Most of the DC shedders could be detected dur ing this period as urinary DCs first appeared within a year post transplant in 88.6% of total patients. But the duration of uri nary DC test remains uncertain. Hirsch et al. 7 recommended that it be done as a routine screening procedure at a 3month interval during the first two years of posttransplant. Singh et al. 8 recommended that it be more frequently for the first six months and then on a yearly basis. In the current study, urinary DC test was done at a 3month interval for more than two years in 5% of patients of the LG shedding group and 33.3% of pa tients of the HG shedding group. But there were two patients who developed PV nephropathy more than two years posttrans plant. Furthermore, at the latest followup, there was a persis tent presence of DCs in more than 40% of patients of the HG shedding group. It would therefore be valid to perform urinary DC test at least on a yearly basis after the first year posttrans plant in patients who have experienced more than a single epi sode of HG shedding.
Another thing to consider is immunomodulation. It has been reported that the allograft function is preserved following re duced immunosuppression even in presumptive cases of PV ne phropathy. 9 There was a gradual decrease in immunosuppres sion in nine patients of the HG shedding group. But there were two patients where DCs were not decreased in number or dis appeared. By contrast, DCs were decreased or disappeared with out reduction of immunosuppression in a substantial percent age of patients, which was clearly in patients of the LG shed ding group. In six patients with viruria or viremia, confirmed Urine plasma
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LG + ---DC, decoy cells; PV PCR, polyomavirus polymerase chain reaction.
on the realtime PCR, the renal function was stable without immunomodulation. The viral load is the most important fac tor for producing PV nephropathy. It remains obscure, however, who can benefit from the decreased immunosuppression. It is therefore necessary to identify viral genotypes and to determine host's immune reaction to the virus, both of which may play a role in tissue injury. 10 Acute rejection is frequently associated in allograft patients with PV nephropathy. 11 Our results showed that the prevalence of acute rejection was relatively higher after DC shedding as compared with prior to it. But there was no difference in the prevalence of acute rejection between the DC shedding group and the control group. This indicates that DC shedding is not a predictor of acute rejection. Acute rejection may be present con currently with PV nephropathy. Renal biopsy should therefore be considered in patients with graft dysfunction accompanied by HG DC shedding.
Limitation of the current study originated from a variability in the methods of urine sampling. The study was conducted us ing either routine smear slides or cytospin slides to estimate the amount of DCs for PV activation. We think this variability might not have a serious impact on the results since there were numer ous DCs in most patients of the HG shedding group with no respect to the methods of urine sampling.
In conclusion, our results indicate that shedding of ≥10 DCs/10 HPF is a clinically significant indicator for sustained shedding and risk for PV nephropathy but it is not a predictor of acute rejection. This implies that a continuous monitoring would be needed for patients with HG shedding even after a transient clearance of DCs.
